LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Becton Dickinson and Co

Open

SectorHealthcare

175.31 1.95

Overview

Share price change

24h

Current

Min

170.98

Max

175.54

Key metrics

By Trading Economics

Income

27M

330M

Sales

104M

5.3B

P/E

Sector Avg

33.915

56.602

EPS

3.35

Dividend yield

2.49

Profit margin

6.259

Employees

70,000

EBITDA

93M

546M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+19.81% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.49%

2.45%

Next Earnings

7 Aug 2025

Next Dividend date

30 Jun 2025

Next Ex Dividend date

9 Jun 2025

Market Stats

By TradingEconomics

Market Cap

-15B

50B

Previous open

173.36

Previous close

175.31

News Sentiment

By Acuity

29%

71%

73 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Becton Dickinson and Co Chart

Past performance is not a reliable indicator of future results.

Related News

1 May 2025, 11:18 UTC

Earnings

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

5 Feb 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7 Nov 2024, 12:59 UTC

Earnings

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7 Nov 2024, 12:56 UTC

Earnings

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1 May 2025, 10:33 UTC

Earnings

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 May 2025, 10:33 UTC

Earnings

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 May 2025, 10:32 UTC

Earnings

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 May 2025, 10:32 UTC

Earnings

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 May 2025, 10:31 UTC

Earnings

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 May 2025, 10:31 UTC

Earnings

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

1 May 2025, 10:30 UTC

Earnings

Becton Dickinson Updates full-Yr Fiscal 2025 Guidance and Provides Estimated Tariff Impact >BDX

1 May 2025, 10:30 UTC

Earnings

Becton Dickinson Sees FY Adj EPS $14.06-Adj EPS $14.34 >BDX

1 May 2025, 10:30 UTC

Earnings

Becton Dickinson 2Q Net $308M >BDX

1 May 2025, 10:30 UTC

Earnings

Becton Dickinson 2Q EPS $1.07 >BDX

1 May 2025, 10:30 UTC

Earnings

Becton Dickinson 2Q Adj EPS $3.35 >BDX

1 May 2025, 10:30 UTC

Earnings

Becton Dickinson 2Q Rev $5.3B >BDX

5 Feb 2025, 21:56 UTC

Earnings

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5 Feb 2025, 21:54 UTC

Earnings

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5 Feb 2025, 21:54 UTC

Earnings

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5 Feb 2025, 21:53 UTC

Earnings

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5 Feb 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5 Feb 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Rev $5.2B >BDX

5 Feb 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q Net $303M >BDX

5 Feb 2025, 21:30 UTC

Earnings

Becton Dickinson 1Q EPS $1.04 >BDX

7 Nov 2024, 11:36 UTC

Earnings

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7 Nov 2024, 11:35 UTC

Earnings

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7 Nov 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q EPS $1.45 >BDX

7 Nov 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7 Nov 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Rev $5.4B >BDX

7 Nov 2024, 11:30 UTC

Earnings

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

Peer Comparison

Price change

Becton Dickinson and Co Forecast

Price Target

By TipRanks

19.81% upside

12 Months Forecast

Average 206.4 USD  19.81%

High 261 USD

Low 172 USD

Based on 12 Wall Street analysts offering 12 month price targets forBecton Dickinson and Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

4

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

167 / 206.99Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

73 / 382 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.